Conventional immunotherapeutic strategies primarily focus on immune cell activation and immune response potentiation through several mechanisms, as follows: immune checkpoint blockade targeting CTLA-4 and PD-1/PD-L1 pathways to counteract immune evasion; tumor vaccines for immune system priming; adoptive cell therapy involving ex vivo immune cell modification and expansion; and monoclonal antibody-mediated specific antigen targetin [2,65,70,71,72]. The gene discussed is CTLA4; the disease is neoplasm.